Inhibition of AR-mediated transcription by binding of octl to a motif enriched in AR-occupied regions

Prostate

Volumn 69, Issue 4, 2009, Pages 392-400

  Jariwala, Unnati ^a   Cogan, Jon P ^a   Jia, Li ^a,b   Frenkel, Baruch ^a   Coetzee, Gerhard A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Androgen receptor; Octl; Prostate cancer; Repression; Target genes; Transcription

Indexed keywords

ANDROGEN RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 1; POU2F1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; ORGANOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; ADENOCARCINOMA; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; AMINO ACID MOTIFS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OCTAMER TRANSCRIPTION FACTOR-1; POINT MUTATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 59849120818     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20893     Document Type: Article

References (35)

1. Balk S. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60(3 Suppl 1):132-138.
2. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20(3-4):207-223.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
4. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351(15):1488-1490.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
6. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11(3):459-476.
7. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32):8253-8261.
8. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20(13):3001-3015.
9. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007.
10. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 2007;21(16):2005-2017.
11. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005;122(1):33-43.
12. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006;38(11):1289-1297.
13. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008;132(6):958-970.
14. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE, Mills IG. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007;8(9):871 -878.
15. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27(3):380-392.
16. Phillips K, Luisi B. The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol 2000;302(5):1023-1039.
17. Prefontaine GG, Walther R, Giffin W, Lemieux ME, Pope L, Hache RJ. Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter. J Biol Chem 1999;274(38):26713 -26719.
18. Kutoh E, Stromstedt PE, Poellinger L. Functional interference between the ubiquitous and constitutive octamer transcription factor 1 (OTF-1) and the glucocorticoid receptor by direct protein-protein interaction involving the homeo subdomain of OTF-1. Mol Cell Biol 1992;12(11):4960-4969.
19. Kakizawa T, Miyamoto T, Ichikawa K, Kaneko A, Suzuki S, Hara M, Nagasawa T, Takeda T, Mori J, Kumagai M, Hashizume K. Functional interaction between Oct-1 and retinoid X receptor. J Biol Chem 1999;274(27):19103-19108.
20. Scarlett CO, Robins DM. In vivo footprinting of an androgen-dependent enhancer reveals an accessory element integral to hormonal response. Mol Endocrinol 1995;9(4):413-423.
21. Scarlett CO, Scheller A, Thompson E, Robins DM. Involvement of an octamer-like sequence within a crucial region ofthe androgen-dependent Slp enhancer. DNA Cell Biol 1997; 16(1):45-57.
22. Gonzalez MI, Robins DM. Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1. J Biol Chem 2001;276(9):6420-6428.
23. Zhao W, Pan J, Wang X, Wu Y, Bauman WA, Cardozo CP. Expression of the muscle arophy factor MAFbx is suppressed by testosterone. Endocrinology 2008;149(11):5449-5460.
24. Remenyi A, Tomilin A, Pohl E, Lins K, Philippsen A, Reinbold R, Scholer HR, Wilmanns M. Differential dimer activities of the transcription factor Oct-1 by DNA-induced interface swapping. Mol Cell 2001;8(3):569-580.
25. Remenyi A, Tomilin A, Scholer HR, Wilmanns M. Differential activity by DNA-induced quarternary structures of POU transcription factors. Biochem Pharmacol 2002;64(5-6):979-984.
26. Tomilin A, Remenyi A, Lins K, Bak H, Leidel S, Vriend G, Wilmanns M, Scholer HR. Synergism with the co-activator OBF-1 (OCA-B, BOB-1) is mediated by a specific POU dimer configuration. Cell 2000;103(6):853-864.
27. Jia L, Berman B, Jariwala U, Yan X, Cogan JP, Walters Allison, Chen T, Buchanan G, Frenkel B, Coetzee GA. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators, and transcriptional capacity. PLOS ONE 2008;3(11):e3645.
28. Luppen CA, Leclerc N, Noh T, Barski A, Khokhar A, Boskey AL, Smith E, Frenkel B. Brief bone morphogenetic protein 2 treatment of glucocorticoid- inhibited MC3T3-E1 osteoblasts rescues commitment-associated cell cycle and mineralization without alteration of Runx2. J Biol Chem 2003;278(45):44995- 45003.
29. Segil N, Roberts SB, Heintz N. Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA-binding activity. Science 1991;254(5039):1814-1816.
30. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54(10):2577-2581.
31. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 2002;277(23):20127-20130.
32. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007;26(17):2459-2470.
33. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004;10(23):8068-8076.
34. Gonzalez MI, Tovaglieri A, Robins DM. Androgen receptor interactions with Oct-1 and Brn-1 are physically and functionally distinct. Mol Cell Endocrinol 2002;190(1 -2):39-49.
35. Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q, Gentzschein E, Pinski JK, Stanczyk FZ, Jones PA, Coetzee GA. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol 2006;26(19):7331 -7341.